Fourteen products, including Tepezza, indicated for thyroid eye disease, and the leukemia drug Blincyto, achieved blockbuster status in 2025
Whilst transdermal patch formulations represent an area of ongoing pharmaceutical research, no GLP-1 patches are currently licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) or approved by the National Institute for Health and Care Excellence (NICE) for use in the United Kingdom
If you're currently utilizing GLP-1 weight loss injections like Ozempic, Wegovy, Mounjaro, or Zepbound, and you've been injecting based on general advice found on social media, there's a real chance you might not be optimizing your medication's absorption
Published epidemiologic estimates suggest that approximately 39% of adults with OSA have moderate-to-severe disease, and 43-54% of those patients meet criteria for obesity the population that tirzepatide is now indicated for